Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study
| Autor: | Birgitt Bieg, U.T. Seyfert, Jochem König, Urban W. Geisthoff, Peter K. Plinkert, Marcus Kubler |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Antifibrinolytic Time Factors medicine.drug_class Medizin Administration Oral Placebo Drug Administration Schedule Double blind Quality of life Double-Blind Method Germany medicine Humans Telangiectasia Aged Diminution Cross-Over Studies business.industry Hematology Middle Aged Antifibrinolytic Agents Clinical trial Epistaxis Treatment Outcome Tranexamic Acid Anesthesia Female Telangiectasia Hereditary Hemorrhagic medicine.symptom business Tranexamic acid medicine.drug |
| Zdroj: | Thrombosis research. 134(3) |
| ISSN: | 1879-2472 |
| Popis: | Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the intention-to-treat analysis. Hemoglobin levels, the primary outcome measure, did not change significantly (p = 0.33). The secondary outcome measure was epistaxis score and patients reported a statistically significant reduction in nosebleeds, equaling a clinically relevant 54% diminution (p = 0.0031), as compared to the placebo period. No severe side effects were observed. Conclusion Tranexamic acid reduces epistaxis in patients with hereditary hemorrhagic telangiectasia. (Clinical trial registration numbers: BfArM 141 CHC 9008–001 and ClinicalTrials.gov NCT01031992 ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect